Hints and tips:
...Recent deals for developers of cancer treatments include Eli Lilly’s $8bn acquisition of Loxo Oncology and GlaxoSmithKline’s $5.1bn purchase of Tesaro....
...Bristol-Myers Squibb agreed to acquire Celgene for $90bn in January, GlaxoSmithKline agreed to buy the US biotech Tesaro for $5.1bn in December, and Eli Lilly said last month it was acquiring Loxo Oncology...
...Then, when she unveiled her first major acquisition — paying a 200 per cent premium to buy oncology-focused US biotech Tesaro for $5bn — critics suggested it was a sad reflection of GSK’s need to rebuild...
...The company’s shares closed 3.8 per cent higher on Wednesday — but even this did not make up for the £5bn sum wiped off GSK’s market value by her decision two weeks ago to pay $5.1bn to acquire Tesaro, a...
...At the same time, she has sought to turn its weaker pharmaceuticals business into a stronger competitor by acquiring cancer-focused US biotech Tesaro this month for $5.1bn....
...Mr Carroll declined to name the companies, although investors sometimes point to a trio of cancer biotechs — Tesaro, Clovis and Puma — as examples of single-product groups that are still independent despite...
...“I think Sanofi’s offer greatly undervalues the company and the Tesaro data only further underlines that.”...
...Deals involving biotechnology company Tesaro and design company Exa could raise $90m and $80m respectively....
International Edition